UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 27, 2008
BOK FINANCIAL CORPORATION
(Exact name of registrant as specified in its charter)
Oklahoma 000-19341 73-1373454
-------- --------- ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
Bank of Oklahoma Tower, Boston Avenue at Second Street, Tulsa, Oklahoma 74172
(Address of principal executive offices)
Registrant's telephone number, including area code:
(918) 588-6000
_____________________N/A___________________________
(Former name or former address, if changes since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425).
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12).
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)).
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c)).
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On May 27, 2008, BOK Financial Corporation (the "Company") entered into a 10b5-1
Repurchase Plan with BOSC, Inc., a registered broker/dealer and wholly owned
subsidiary, to purchase Company common stock in compliance with Rule 10b5-1 of
the Securities Exchange Act of 1934, as amended (the "10b5-1 Plan"). The 10b5-1
Plan will allow the Company's Rule 10b-18 share repurchase program to continue
during periods when the Company would normally not be active in the market due
to its internal trading black out periods and may be aware of material nonpublic
information.
On April 26, 2005, the Company's board of directors authorized the Company to
repurchase up to two million shares of the Company's common stock under the
repurchase program. As of March 31, 2008, the Company had repurchased 709,073
shares under the repurchase program.
Pursuant to the terms of the 10b5-1 Plan, BOSC, Inc., as agent for the Company
and through a mirrored execution agreement with Pershing LLC, will purchase
varying percentages of the maximum daily volume allowable under Rule 10b-18 when
the Company is trading at various price ranges. Any purchases under the 10b5-1
Plan will be disclosed publicly through appropriate filings with the Securities
and Exchange Commission.
The description of the Plan in this Item 1.01 is qualified in its entirety by
reference to the text of the plan, a copy of which is filed as Exhibit 10.1 to
this Form 8-K and incorporated herein by reference.
ITEM 9.01. Financial Statements and Exhibits
(c) Exhibits
+10.1 10b5-1 Repurchase Plan between BOK Financial Corporation and BOSC, Inc.
dated May 27, 2008
+ The Company has requested confidential treatment of certain information
contained in this exhibit. Such information has been filed separately with
the Securities and Exchange Commission pursuant to the Company's
application for confidential treatment under 17 C.F.R. ss.ss. 200.80(b)(4)
and 240.24b-2.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BOK FINANCIAL CORPORATION
By: /s/ Steven E. Nell
--------------------------------
Steven E. Nell
Executive Vice President
Chief Financial Officer
Date: May 27, 2008
Exhibit Index
Exhibit No. Description
+10.1 10b5-1 Repurchase Plan between BOK Financial Corporation
and BOSC, Inc. dated May 27, 2008
+ The Company has requested confidential treatment of certain information
contained in this exhibit. Such information has been filed separately with the
Securities and Exchange Commission pursuant to the Company's application for
confidential treatment under 17 C.F.R. ss.ss. 200.80(b)(4) and 240.24b-2.